ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN PREDICTING PROGRESSION AND RECURRENCE OF PROSTATE AND BLADDER CANCER: CURRENT INSIGHTS AND FUTURE DIRECTIONS
Abstract
Urologic cancers such as prostate and bladder malignancies are characterized by considerable heterogeneity in their biological behavior and clinical outcomes. Accurate prediction of disease progression and recurrence plays a critical role in improving treatment planning, optimizing follow-up strategies, and advancing personalized medicine. Traditional prognostic tools, which rely primarily on clinical and pathological features, often lack the precision required for individualized risk assessment. In recent years, Artificial Intelligence and Machine Learning have emerged as powerful tools in oncological research, offering approaches to prognostic modelling based on large-scale, high-dimensional data.
This review synthesizes findings from thirty-nine recent studies that investigated the use of artificial intelligence in predicting progression, recurrence, survival, and treatment outcomes in prostate and bladder cancers. The included works applied diverse machine learning techniques to data types such as magnetic resonance imaging, whole-slide pathology images, gene expression profiles, and electronic health records. Many models demonstrated improved predictive performance over traditional methods, particularly when integrating multimodal datasets. Furthermore, external validation in multicenter cohorts was increasingly reported, supporting the generalizability of results.
Despite promising advances, the widespread clinical application of artificial intelligence in urologic oncology remains limited. Challenges include variability in data sources, lack of standardization, limited interpretability of models, and ethical concerns related to data privacy and fairness. Nonetheless, the integration of artificial intelligence into clinical decision-making workflows holds substantial promises for enhancing prognostic accuracy and supporting personalized management strategies. Future efforts should focus on harmonized methodologies, prospective validation, and transparent reporting to fully realize the clinical potential of these technologies.
References
Abbas, S., Shafik, R., Soomro, N., Heer, R., & Adhikari, K. (2025). AI predicting recurrence in non-muscle-invasive bladder cancer: Systematic review with study strengths and weaknesses. Frontiers in Oncology, 14, 1509362. https://doi.org/10.3389/fonc.2024.1509362
Bang, S., Ahn, Y. J., & Koo, K. C. (2025). Harnessing machine learning to predict prostate cancer survival: A review. Frontiers in Oncology, 14, 1502629. https://doi.org/10.3389/fonc.2024.1502629
Bashkami, A., Nasayreh, A., Makhadmeh, S. N., et al. (2024). A review of artificial intelligence methods in bladder cancer: Segmentation, classification, and detection. Artificial Intelligence Review, 57, 339. https://doi.org/10.1007/s10462-024-10953-6
Bergero, M. A., Martínez, P., Modina, P., et al. (2025). Artificial intelligence model for predicting early biochemical recurrence of prostate cancer after robotic-assisted radical prostatectomy. Scientific Reports, 15(1), 30822. https://doi.org/10.1038/s41598-025-16362-1
Cao, L., He, R., Zhang, A., et al. (2025). Development of a deep learning system for predicting biochemical recurrence in prostate cancer. BMC Cancer, 25(1), 232. https://doi.org/10.1186/s12885-025-13628-9
Cicchetti, R., Amparore, D., Tamborino, F., et al. (2025). The use of artificial intelligence in urologic oncology: Current insights and challenges. Research and Reports in Urology, 17, 293–308. https://doi.org/10.2147/RRU.S526184
Dai, L., Ye, K., Yao, G., et al. (2025). Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: A SEER-based study. BMC Cancer, 25(1), 523. https://doi.org/10.1186/s12885-025-13942-2
Ejaz, Z. H., Shaikh, R. H., Fatimi, A. S., & Khan, S. R. (2025). Unlocking artificial intelligence, machine learning and deep learning to combat therapeutic resistance in metastatic castration-resistant prostate cancer: A comprehensive review. Ecancermedicalscience, 19, 1953. https://doi.org/10.3332/ecancer.2025.1953
Eminaga, O., Shkolyar, E., Breil, B., et al. (2022). Artificial intelligence-based prognostic model for urologic cancers: A SEER-based study. Cancers (Basel), 14(13), 3135. https://doi.org/10.3390/cancers14133135
Fan, B., Zhang, L., Cui, H., et al. (2025). Development of a machine learning-based model to predict urethral recurrence following radical cystectomy: A multicentre retrospective study and updated meta-analysis. Scientific Reports, 15(1), 19573. https://doi.org/10.1038/s41598-025-04893-6
Ferro, M., Falagario, U. G., Barone, B., et al. (2023). Artificial intelligence in the advanced diagnosis of bladder cancer: Comprehensive literature review and future advancement. Diagnostics (Basel), 13(13), 2308. https://doi.org/10.3390/diagnostics13132308
He, Q., Xiao, B., Tan, Y., et al. (2024). Integrated multicenter deep learning system for prognostic prediction in bladder cancer. npj Precision Oncology, 8(1), 233. https://doi.org/10.1038/s41698-024-00731-6
Hu, C., Qiao, X., Huang, R., Hu, C., Bao, J., & Wang, X. (2024). Development and validation of a multimodality model based on whole-slide imaging and biparametric MRI for predicting postoperative biochemical recurrence in prostate cancer. Radiology Imaging Cancer, 6(3), e230143. https://doi.org/10.1148/rycan.230143
Jobczyk, M., Stawiski, K., Kaszkowiak, M., et al. (2022). Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer. European Urology Oncology, 5(1), 109–112. https://doi.org/10.1016/j.euo.2021.05.006
Khoraminia, F., Fuster, S., Kanwal, N., et al. (2023). Artificial intelligence in digital pathology for bladder cancer: Hype or hope? A systematic review. Cancers (Basel), 15(18), 4518. https://doi.org/10.3390/cancers15184518
Kwong, J. C. C., Wu, J., Malik, S., et al. (2024). Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: A systematic review using APPRAISE-AI. npj Digital Medicine, 7, 98. https://doi.org/10.1038/s41746-024-01088-7
Laurie, M. A., Zhou, S. R., Islam, M. T., Shkolyar, E., Xing, L., & Liao, J. C. (2024). Bladder cancer and artificial intelligence: Emerging applications. Urologic Clinics of North America, 51(1), 63–75. https://doi.org/10.1016/j.ucl.2023.07.002
Lee, H. W., Kim, E., Na, I., Kim, C. K., Seo, S. I., & Park, H. (2023). Novel multiparametric magnetic resonance imaging-based deep learning and clinical parameter integration for the prediction of long-term biochemical recurrence-free survival in prostate cancer after radical prostatectomy. Cancers (Basel), 15(13), 3416. https://doi.org/10.3390/cancers15133416
Li, W., Hu, R., Zhang, Q., et al. (2025). Artificial intelligence in prostate cancer. Chinese Medical Journal (English), 138(15), 1769–1782. https://doi.org/10.1097/CM9.0000000000003689
Liu, J., Zhang, H., Woon, D. T. S., Perera, M., & Lawrentschuk, N. (2024). Predicting biochemical recurrence of prostate cancer post-prostatectomy using artificial intelligence: A systematic review. Cancers (Basel), 16(21), 3596. https://doi.org/10.3390/cancers16213596
Luo, L., Wang, X., & Xie, H. (2024). Role of [18F]-PSMA-1007 PET radiomics for seminal vesicle invasion prediction in primary prostate cancer. Computer Methods and Programs in Biomedicine, 183, 109249. https://doi.org/10.1016/j.compbiomed.2024.109249
Ma, X., Zhang, Q., He, L., et al. (2024). Artificial intelligence application in the diagnosis and treatment of bladder cancer: Advances, challenges, and opportunities. Frontiers in Oncology, 14, 1487676. https://doi.org/10.3389/fonc.2024.1487676
Peng, C., Gong, C., Zhang, X., & Liu, D. (2025). A prognostic model for highly aggressive prostate cancer using interpretable machine learning techniques. Frontiers in Medicine (Lausanne), 12, 1512870. https://doi.org/10.3389/fmed.2025.1512870
Piran Nanekaran, N., Felefly, T. H., Schieda, N., Morgan, S. C., Mittal, R., & Ukwatta, E. (2024). Prediction of prostate cancer recurrence after radiotherapy using a fused machine learning approach: Utilizing radiomics from pretreatment T2W MRI images with clinical and pathological information. Biomedical Physics & Engineering Express. https://doi.org/10.1088/2057-1976/ad8201
Porreca, A., Di Nicola, M., Lucarelli, G., et al. (2024). Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database. Urologic Oncology, 42(3), 69.e17–69.e25. https://doi.org/10.1016/j.urolonc.2024.01.001
Riaz, I. B., Harmon, S., Chen, Z., Naqvi, S. A. A., & Cheng, L. (2024). Applications of artificial intelligence in prostate cancer care: A path to enhanced efficiency and outcomes. ASCO Educational Book, 44(3), 438516. https://doi.org/10.1200/EDBK_438516
Simon, B. D., Harmon, S. A., Merriman, K. M., et al. (2025). A multimodal automated deep learning-based model for predicting biochemical recurrence of prostate cancer following prostatectomy from baseline MRI and presurgical clinical covariates. Clinical Imaging, 126, 110579. https://doi.org/10.1016/j.clinimag.2025.110579
Singh, G., Agrawal, M., Talwar, G., et al. (2024). Artificial intelligence in prostate cancer: The potential of machine learning models and neural networks to predict biochemical recurrence after robot-assisted radical prostatectomy. Indian Journal of Urology, 40(4), 260–265. https://doi.org/10.4103/iju.iju_75_24
Tătaru, O. S., Vartolomei, M. D., Rassweiler, J. J., et al. (2021). Artificial intelligence and machine learning in prostate cancer patient management: Current trends and future perspectives. Diagnostics (Basel), 11(2), 354. https://doi.org/10.3390/diagnostics11020354
Tang, Y., Li, S., Zhu, L., et al. (2024). Improve clinical feature-based bladder cancer survival prediction models through integration with gene expression profiles and machine learning techniques. Heliyon, 10(20), e38242. https://doi.org/10.1016/j.heliyon.2024.e38242
Vidiyala, N., Parupathi, P., Sunkishala, P., et al. (2025). Artificial intelligence: A new era in prostate cancer diagnosis and treatment. International Journal of Pharmaceutics, 683, 126024. https://doi.org/10.1016/j.ijpharm.2025.126024
Wang, H., Zhang, M., Miao, J., et al. (2023). Deep learning signature based on multiphase enhanced CT for bladder cancer recurrence prediction: A multi-center study. EClinicalMedicine, 66, 102352. https://doi.org/10.1016/j.eclinm.2023.102352
Wang, Y., Zhu, H., & Ren, J. (2025). Integrative machine learning models predict prostate cancer diagnosis and biochemical recurrence risk: Advancing precision oncology. npj Digital Medicine, 8, 524. https://doi.org/10.1038/s41746-025-01930-6
Wu, S. Y., Wang, Y., Fan, P., et al. (2025). Bi-parametric MRI-based quantification radiomics model for the noninvasive prediction of histopathology and biochemical recurrence after prostate cancer surgery: A multicenter study. Abdominal Radiology (New York), 50(9), 4320–4330. https://doi.org/10.1007/s00261-025-04873-4
Xu, H., Liu, Z., Weng, S., et al. (2022). Artificial intelligence-driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multi-center integration analysis. Molecular Oncology, 16(22), 4023–4042. https://doi.org/10.1002/1878-0261.13313
Zhang, J., Pan, J., Lin, J., et al. (2025). Prognostic and predictive value of machine learning-based biomarker and pathomics signatures in patients with prostate cancer. Cancer Science, 116(10), 2893–2906. https://doi.org/10.1111/cas.70149
Zhang, X., & Ma, L. (2024). Predictive value of the total bilirubin and CA50 screened based on machine learning for recurrence of bladder cancer patients. Cancer Management and Research, 16, 537–546. https://doi.org/10.2147/CMAR.S457269
Zhu, M., Gu, Z., Chen, F., Chen, X., Wang, Y., & Zhao, G. (2024a). Application of artificial intelligence in the diagnosis and treatment of urinary tumors. Frontiers in Oncology, 14, 1440626. https://doi.org/10.3389/fonc.2024.1440626
Zhu, M., Sali, R., Baba, F., et al. (2024b). Artificial intelligence in pathologic diagnosis, prognosis and prediction of prostate cancer. American Journal of Clinical and Experimental Urology, 12(4), 200–215. https://doi.org/10.62347/JSAE9732
Copyright (c) 2025 Krystian Czyżykowski, Anna Maria Gęsińska, Helena Szelka, Bartosz Golis, Paweł Edyko, Alicja Babula, Wiktor Golus, Katarzyna Andrzejewska, Zuzanna Przybyła, Hubert Woźniak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
